CARM Stock Overview
A clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Carisma Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$3.16 |
| 52 Week Low | US$0.38 |
| Beta | 0 |
| 1 Month Change | -52.83% |
| 3 Month Change | -60.10% |
| 1 Year Change | -87.52% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.43% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%
Dec 06
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky
Sep 02US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results
May 12Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%
Apr 19We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop
Jan 21The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%
Dec 07Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)
Nov 12Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Shareholder Returns
| CARM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.8% | -3.3% | -2.2% |
| 1Y | -87.5% | -1.9% | 23.9% |
Return vs Industry: CARM underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CARM underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| CARM volatility | |
|---|---|
| CARM Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CARM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CARM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 107 | Steve Kelly | www.carismatx.com |
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
Carisma Therapeutics, Inc. Fundamentals Summary
| CARM fundamental statistics | |
|---|---|
| Market cap | US$17.45m |
| Earnings (TTM) | -US$63.80m |
| Revenue (TTM) | US$20.27m |
0.8x
P/S Ratio-0.3x
P/E RatioIs CARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CARM income statement (TTM) | |
|---|---|
| Revenue | US$20.27m |
| Cost of Revenue | US$63.51m |
| Gross Profit | -US$43.24m |
| Other Expenses | US$20.56m |
| Earnings | -US$63.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | -213.35% |
| Net Profit Margin | -314.78% |
| Debt/Equity Ratio | 0% |
How did CARM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Carisma Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Justin Zelin | BTIG |
| Naureen Quibria | Capital One Securities, Inc. |